Abstract: Metabolomic analysis of biological fluids and tissues has become an increasingly routine tool in the biological toolbox. However, challenges remain to be overcome, including developing strategies to maximise coverage of the metabolome without requiring large sample volumes. Here we describe a multimodal strategy that combines data using both LC-MS and GC-MS from a unique vial with a sample of plasma (20µl) or a sample of brain tissue (3mg). Using a split phase extraction the non-aqueous phase was analyzed by reversed phase (RP) LC-MS, whilst the aqueous phase was analyzed using hydrophilic liquid interaction chromatography (HILIC)LC-MS, with both phases also analysed using GC-MS after derivatization of the extract. Analytical performance was assessed in 7 rat cerebellum samples and a pilot study of 40 plasma samples (20 vs. 20: AD vs. healthy controls). The method, which uses four hours of instrument time, measured 20,707 metabolite features in brain samples and 17,266 in plasma samples, from those 44.1% features displayed CV's below 15% and 75.2% below 30%. The method has potential to resolve subtle biological differences and to correlate metabolite composition directly to clinical outcomes including MMSE, age and ADCS-ADL. This method can acquire in the order of 20K metabolic features when low volumes are available.
Introduction
Metabolomics is the unbiased analysis of the composition of small molecule metabolites in a given biological tissue or bio-fluid under a specific set of environmental conditions [1, 2] . In recent years the development of new methods has seen metabolomics progress from a novel analytical technique towards a mainstay of the biological toolbox. However, before this transformation can be completed a number of technical challenges remain to be overcome, foremost among these is maximizing coverage of the metabolome [3, 4] . A number of previous studies have done this by utilizing multiple complimentary techniques including liquid chromatography -mass spectrometry (LC-MS), nuclear magnetic resonance spectroscopy (NMR) and gas chromatography -mass spectrometry (GC-MS) [5] [6] [7] . However, these strategies require individual sample preparation techniques which significantly increases the volume of sample and potentially variation and analysis time.
Dementia represents a major cause of morbidity and mortality worldwide, with Alzheimer's disease (AD) accounting for 60-80% of all dementia cases [8] , which is characterized by a progressive cognitive decline, starting with problems with short term memory progressing to disorientation, mood swings and language problems [9, 10] . In 2006 it was estimated that worldwide 46 million people suffered from AD [11] with the estimated financial cost expected to reach $1 trillion by 2018 [12] With an increasing elderly population the prevalence of AD is expected to increase fourfold to 131.5 million sufferers by 2050, significantly increasing both the social and financial burden represented by AD. Alzheimer's disease is known to have a long prodromal phase to the disease in which pathology accumulates without the presence of symptoms, making the discovery of a panel of biomarkers that can identify individuals in this phase of the disease. Current efforts to do this have been unsuccessful but it is hoped by extending our coverage of the metabolome to include metabolites previously unstudied in AD will help to overcome this.
To this end we developed a strategy that enables 6 analytical assays (4 LC-MS and 2 GC-MS) to be applied to a single in-vial dual extraction utilising as little as 3mg of brain tissue [13] or 20µl of plasma [14] . The method was designed to analyse samples in the future such as human brain, prioritising the information acquired over the length of the analysis. The robustness and utility of this strategy was assessed by combining all the data and applying the method to 7 rat cerebellum samples and a pilot experiment of plasma samples of 20 Alzheimer's patients versus 20 healthy age matched controls split into stable and declining individuals to allow us to assess the ability of the platform to detect both large and subtle metabolic differences.
Experimental section

Chemicals and Reagents
All solvents including acetonitrile, ammonium formate, formic acid, methanol, methyl tertiary butyl ether (MTBE), toluene and water were all LC-MS grade purchased from Sigma-Aldrich with the exception of acetonitrile which was purchased from VWR international. Three internal standards were added for LC-MS analysis, L-serine Sample derivatisation for GC-MS analysis was performed using N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% trimethylchlorosilane (TMCS) purchased from Sigma-Aldrich.
Biological Material
Brain tissue samples were obtained from rat cerebellums which were harvested as per Schedule 
Controls
Alzheimer's 
Sample Preparation
The in vial dual extractions (IVDE) were performed as previously described for plasma [14] and brain tissue [13] , the workflow is summarised in. After all of the LC-MS analysis had been performed 
Data Acquisition
The HILIC and reversed phase LC-MS analysis was performed on a Waters ultra-performance liquid chromatogrpahy (UPLC) system coupled to a quadrupole rime-of-flight (Q-ToF) mass spectrometer (Waters, Milford, MA, USA) as described previously [13, 14] . GC-MS analysis was carried out on a 
Data Processing
Initially all raw data files were converted into an mzXML format, LC-MS files were converted using msConvert (ProteoWizard), whilst GC-MS files were converted using GCMS Solutions ® (Shimadzu).
Converted data files were analyzed using XCMS, performed in the open source software package R, picking was performed using a "massifquant" method for the GCMS data allows isotope trace feature detection and a ''centwave'' method for LCMS data, allows the deconvolution of closely eluting or slightly overlapping peaks. Metabolite features were defined as any peak with an average intensity 5 times higher in the analytical samples than is measured for this peak in the extraction blanks.
Measured metabolite features from all assays were combined into a single multimodal dataset that selection to create curated models was performed by iteratively removing variables using the variable influence to projections plot to achieve the fitted model with the optimal R2 and Q2 values [15] . The predictive ability of the generated OPLS models were validated by using permutation test [16] . The results showed that none of the permuted Q 2 values is higher than the one in the original model which confirms the reliability of the produced models.
Results and Discussion
Reproducibility test and data quality of the method
The total time of this method was four hours which is unusually long in metabolomics, where methods need to be high-throughput. The present method was designed to acquire as much information as possible from one sample and the instrument time and cost of analysis were increased to achieve this end. The quality of the generated data was assessed by looking at the compositional similarity of QC samples based on all metabolite features using PCA (Figure 2 ). QCs clustered apart from QC1 which was the first injection into the run (highlighted in a box), the other QCs clustered once the columns were equilibrated, hence showing a clustering lower than biological variance suggesting across run reproducibility and stability. In a PCA analysis of just the QC samples it could be seen that the analytical drift across the run accounted for 17.2% of the overall variance observed in the QC. The selectivity and reproducibility of the method was assessed in both brain tissue (Table 2 ) and plasma (Table 3) by determining the number of peaks measured and their relative variance. In the raw brain data, it can be seen that the peaks detected in the 4 LC-MS methods were a total of 9459 peaks (signal/noise > 5), and reproducible with 61.8% of the metabolite features with coefficients of variance (CV) of less than 15% and 84.0% with CV's below 30% ( Table 2 ). The data generated by GC-MS was also shown to be measuring 11248 (signal/noise > 5) metabolite features, however the reproducibility of the data is poor with only 1.5% of metabolite features showing CV's of less than 15% and 12.3% below 30% CV's. To improve the reproducibility, the data was normalized to total ion count (TIC), with this normalization significantly improving the reproducibility with 34.4% of total peaks now with CV's of less than 15% and 68.7 below 30%, however normalization appeared to have a limited effect on the LC-MS data. The initial selectivity and reproducibility of the method in plasma was assessed in the 8 pooled QC samples run during the pilot experiment. As with the data generated from brain tissue the LC-MS data was shown to be measuring a total of 9551 metabolite features as well as highly reproducible with 36.9% of peaks showing CV's of less than 15%, and 61.8% below 30% CV's, whilst 9.8% of the 7715 of the GC-MS metabolite features showing CV's lower than 15% and only 17.3% with CV's below 30%. The data was normalized to TIC, produced a modest increase in the reproducibility of the RP data from 33.3% and 74.0% to 50.7% and 75.2% and HILIC data from 41% and 60.5% to 50.5% and 71% with CV's below 15% and 30% respectively. Normalization of the GC-MS data also improved reproducibility from 16.5%
to 30.9% with CV's below 15% and 30%. Inspection of the non-aqueous phase data which shows the least number of features with CV's <30% compared to LC-MS and GC-MS aqueous method. However, during method development the non-aqueous phase achieved CV's (data not shown) in line with the brain experiments shown in Table 2 . The aqueous phase showed 34.9% of features with CV's below 15%, and 63.3% below 30% also in line with the brain experiment. Having shown the method was reproducible the next stage in assessing its performance was to determine its ability to detect differences in a small pilot between biological classes using multimodal multivariate data analysis.
Curated models were generated using both raw and TIC normalized data from all of the 6 platforms groups. This analysis showed that the 'declining' control samples clustered in the same primary clade as the AD samples suggesting that they were more compositionally similar to the AD samples than they are to the 'stable' controls. Whilst these samples were diagnosed clinically as controls and showed no difference in cognitive ability at baseline, at a 12 month follow up these individuals had exhibited a significant decline in cognitive function (0.83 MMSE points, p = 0.019). When metabolite features were considered individually it could be seen that the 'declining' controls had a similar abundance to that which is observed in the AD samples or is intermediary between the 'stable' controls and AD samples (Figure 4 ). Of the metabolite features that were important for driving the separation between the two groups of controls we annotated the excitatory neurotransmitter glutamate (Figure 4 ) which has previously been linked to the pathology and progression of Alzheimer's disease [17] [18] [19] [20] [21] . In this small pilot metabolic shifts potentially associated with subtle differences in biological phenotypes were observed. Hence, this multimodal method was able to discriminate 'stable', 'declining' controls and AD patients using a PCA, however promising this result, the number of samples does not warrant metabolite identification which will be performed once features are validated in a follow up larger scale study.
Having observed that this method could discriminate between defined biological classes we wanted to determine whether metabolite composition could be directly correlated with a range of relevant clinical measures. Determining the association between metabolite composition and clinical outcomes was done using OPLS analysis with MMSE, age and ADCS-ADL set as Y variables. Using SIMCA's inner relations plot it can be seen that metabolite composition correlates with MMSE ( Figure 5A 
Conclusions
This study illustrates the utility of combining metabolomics data to measure large numbers of metabolite features from small sample volumes with multivariate statistics, to detect metabolic differences to clinical outcomes. It is hoped that by improving our ability to measure the metabolome using multimodal data, including proteomics and genomics and increasing sample numbers, diagnostic and prognostic markers of AD pathology can be discovered.
